©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Contemporary management of upper tract urothelial cell carcinoma
Kellen Choi, Samuel Deem, Department of Urology, Charleston Area Medical Center, Charleston, WV 25304, United States
Ryan McCafferty, Department of Anesthesiology PGY-1, Larkin Community Hospital, South Miami, FL 33143, United States
Author contributions: Choi K wrote the paper; McCafferty R and Deem S performed literature review.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Correspondence to: Kellen Choi, DO, Department of Urology, Charleston Area Medical Center, 3200 MacCorkle Ave, S.E., Charleston, WV 25304, United States. bchoi@alum.unthsc.edu
Telephone: +1-304-3885280 Fax: +1-304-3885291
Received: April 5, 2016
Peer-review started: April 8, 2016
First decision: July 14, 2016
Revised: November 7, 2016
Accepted: December 27, 2016
Article in press: December 29, 2016
Published online: March 24, 2017
Processing time: 330 Days and 14.7 Hours
Peer-review started: April 8, 2016
First decision: July 14, 2016
Revised: November 7, 2016
Accepted: December 27, 2016
Article in press: December 29, 2016
Published online: March 24, 2017
Processing time: 330 Days and 14.7 Hours
Core Tip
Core tip: To review the current literature on upper tract urothelial cell carcinoma (UTUCC) and provide a contemporary management plan for treatment based on best available evidence. Large randomized controlled trials are lacking in UTUCC due to the fortunately rare occurrence of the disease. Treatment recommendations for the primary lesion, imaging, and follow-up in this review are based on the stage and grade of the tumor. Early diagnosis and aggressive treatment remains the mainstay of therapy for UTUCC.